Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis

Changlin Fu, Smriti Bardhan, Nicolae D. Cetateanu, Barbara D. Wamil, Yufen Wang, Ergang Shi, Christo Venkov, F. Michael Yakes, Ray L. Mernaugh, Carl G. Hellerqvist, He Ping Yan, Clint Carter, David L. Page, Robert (Stephen) Lloyd

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor growth in mice and humans. CM101 also targets neonatal lung and adult sheep lung endothelial cells. A gene encoding a transmembrane protein that interacts with CM101 was isolated from a sheep lung endothelial cell cDNA library. The gene, termed sp55, encodes a 495-amino acid polypeptide. COS-7 cells transfected with a vector containing sp55 express the SP55 protein-bound CM101 in a concentration-dependent manner. Stably transfected CHO cells also bound CM101. The corresponding human gene, hp59, was isolated from a human fetal lung cDNA library and had a predicted identity to SP55 of 86% over 495 amino acids. HP59 protein was shown by immunohistochemistry to be present in the pathological tumor vasculature of the lung, breast, colon, and ovary, but not in the normal vasculature, suggesting that the protein may be critical to pathological angiogenesis. The hp59 gene and/or the HP59 protein was not expressed in a variety of normal tissues, but was significantly expressed in human fetal lung, consistent with the pathophysiology of Group B streptococcus infections in neonates. Mice immunized with HP59 and SP55 peptides showed significant attenuation of tumor growth. Immunization effectively inhibited both the tumor angiogenesis and vasculogenesis processes, as evidenced by lack of both HP59- and CD34-positive vessels. These results and the immunohistochemistry data suggest a therapeutic potential for the CM101 target protein HP59 both as a drug target and as a vaccine against pathoangiogenesis.

Original languageEnglish (US)
Pages (from-to)4182-4194
Number of pages13
JournalClinical Cancer Research
Volume7
Issue number12
StatePublished - 2001
Externally publishedYes

Fingerprint

Membrane Proteins
Lung
Pathologic Neovascularization
Neoplasms
Proteins
Streptococcus agalactiae
Gene Library
Genes
Sheep
Therapeutics
Endothelial Cells
Immunohistochemistry
Amino Acids
Peptides
CHO Cells
COS Cells
Growth
Polysaccharides
Culture Media
streptococcal polysaccharide type III group B

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. / Fu, Changlin; Bardhan, Smriti; Cetateanu, Nicolae D.; Wamil, Barbara D.; Wang, Yufen; Shi, Ergang; Venkov, Christo; Yakes, F. Michael; Mernaugh, Ray L.; Hellerqvist, Carl G.; Yan, He Ping; Carter, Clint; Page, David L.; Lloyd, Robert (Stephen).

In: Clinical Cancer Research, Vol. 7, No. 12, 2001, p. 4182-4194.

Research output: Contribution to journalArticle

Fu, C, Bardhan, S, Cetateanu, ND, Wamil, BD, Wang, Y, Shi, E, Venkov, C, Yakes, FM, Mernaugh, RL, Hellerqvist, CG, Yan, HP, Carter, C, Page, DL & Lloyd, RS 2001, 'Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis', Clinical Cancer Research, vol. 7, no. 12, pp. 4182-4194.
Fu, Changlin ; Bardhan, Smriti ; Cetateanu, Nicolae D. ; Wamil, Barbara D. ; Wang, Yufen ; Shi, Ergang ; Venkov, Christo ; Yakes, F. Michael ; Mernaugh, Ray L. ; Hellerqvist, Carl G. ; Yan, He Ping ; Carter, Clint ; Page, David L. ; Lloyd, Robert (Stephen). / Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis. In: Clinical Cancer Research. 2001 ; Vol. 7, No. 12. pp. 4182-4194.
@article{ad2bae427488432c979e3ff2ff7bd041,
title = "Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis",
abstract = "CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor growth in mice and humans. CM101 also targets neonatal lung and adult sheep lung endothelial cells. A gene encoding a transmembrane protein that interacts with CM101 was isolated from a sheep lung endothelial cell cDNA library. The gene, termed sp55, encodes a 495-amino acid polypeptide. COS-7 cells transfected with a vector containing sp55 express the SP55 protein-bound CM101 in a concentration-dependent manner. Stably transfected CHO cells also bound CM101. The corresponding human gene, hp59, was isolated from a human fetal lung cDNA library and had a predicted identity to SP55 of 86{\%} over 495 amino acids. HP59 protein was shown by immunohistochemistry to be present in the pathological tumor vasculature of the lung, breast, colon, and ovary, but not in the normal vasculature, suggesting that the protein may be critical to pathological angiogenesis. The hp59 gene and/or the HP59 protein was not expressed in a variety of normal tissues, but was significantly expressed in human fetal lung, consistent with the pathophysiology of Group B streptococcus infections in neonates. Mice immunized with HP59 and SP55 peptides showed significant attenuation of tumor growth. Immunization effectively inhibited both the tumor angiogenesis and vasculogenesis processes, as evidenced by lack of both HP59- and CD34-positive vessels. These results and the immunohistochemistry data suggest a therapeutic potential for the CM101 target protein HP59 both as a drug target and as a vaccine against pathoangiogenesis.",
author = "Changlin Fu and Smriti Bardhan and Cetateanu, {Nicolae D.} and Wamil, {Barbara D.} and Yufen Wang and Ergang Shi and Christo Venkov and Yakes, {F. Michael} and Mernaugh, {Ray L.} and Hellerqvist, {Carl G.} and Yan, {He Ping} and Clint Carter and Page, {David L.} and Lloyd, {Robert (Stephen)}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "4182--4194",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesis

AU - Fu, Changlin

AU - Bardhan, Smriti

AU - Cetateanu, Nicolae D.

AU - Wamil, Barbara D.

AU - Wang, Yufen

AU - Shi, Ergang

AU - Venkov, Christo

AU - Yakes, F. Michael

AU - Mernaugh, Ray L.

AU - Hellerqvist, Carl G.

AU - Yan, He Ping

AU - Carter, Clint

AU - Page, David L.

AU - Lloyd, Robert (Stephen)

PY - 2001

Y1 - 2001

N2 - CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor growth in mice and humans. CM101 also targets neonatal lung and adult sheep lung endothelial cells. A gene encoding a transmembrane protein that interacts with CM101 was isolated from a sheep lung endothelial cell cDNA library. The gene, termed sp55, encodes a 495-amino acid polypeptide. COS-7 cells transfected with a vector containing sp55 express the SP55 protein-bound CM101 in a concentration-dependent manner. Stably transfected CHO cells also bound CM101. The corresponding human gene, hp59, was isolated from a human fetal lung cDNA library and had a predicted identity to SP55 of 86% over 495 amino acids. HP59 protein was shown by immunohistochemistry to be present in the pathological tumor vasculature of the lung, breast, colon, and ovary, but not in the normal vasculature, suggesting that the protein may be critical to pathological angiogenesis. The hp59 gene and/or the HP59 protein was not expressed in a variety of normal tissues, but was significantly expressed in human fetal lung, consistent with the pathophysiology of Group B streptococcus infections in neonates. Mice immunized with HP59 and SP55 peptides showed significant attenuation of tumor growth. Immunization effectively inhibited both the tumor angiogenesis and vasculogenesis processes, as evidenced by lack of both HP59- and CD34-positive vessels. These results and the immunohistochemistry data suggest a therapeutic potential for the CM101 target protein HP59 both as a drug target and as a vaccine against pathoangiogenesis.

AB - CM101, a polysaccharide isolated from the culture medium of Group B streptococcus, a neonatal pathogen, targets pathological angiogenesis and inhibits tumor growth in mice and humans. CM101 also targets neonatal lung and adult sheep lung endothelial cells. A gene encoding a transmembrane protein that interacts with CM101 was isolated from a sheep lung endothelial cell cDNA library. The gene, termed sp55, encodes a 495-amino acid polypeptide. COS-7 cells transfected with a vector containing sp55 express the SP55 protein-bound CM101 in a concentration-dependent manner. Stably transfected CHO cells also bound CM101. The corresponding human gene, hp59, was isolated from a human fetal lung cDNA library and had a predicted identity to SP55 of 86% over 495 amino acids. HP59 protein was shown by immunohistochemistry to be present in the pathological tumor vasculature of the lung, breast, colon, and ovary, but not in the normal vasculature, suggesting that the protein may be critical to pathological angiogenesis. The hp59 gene and/or the HP59 protein was not expressed in a variety of normal tissues, but was significantly expressed in human fetal lung, consistent with the pathophysiology of Group B streptococcus infections in neonates. Mice immunized with HP59 and SP55 peptides showed significant attenuation of tumor growth. Immunization effectively inhibited both the tumor angiogenesis and vasculogenesis processes, as evidenced by lack of both HP59- and CD34-positive vessels. These results and the immunohistochemistry data suggest a therapeutic potential for the CM101 target protein HP59 both as a drug target and as a vaccine against pathoangiogenesis.

UR - http://www.scopus.com/inward/record.url?scp=0035678089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035678089&partnerID=8YFLogxK

M3 - Article

C2 - 11751519

AN - SCOPUS:0035678089

VL - 7

SP - 4182

EP - 4194

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -